Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies

Next Previous
X
Search
Trial Profile

Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vopratelimab (Primary) ; Ipilimumab; Nivolumab; Pembrolizumab
  • Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ICONIC
  • Sponsors Jounce Therapeutics

    • Most Recent Events

    • 05 May 2022 Results of an analysis assessed ICOS high CD4 T cell populations and predictors of response published in the Clinical Cancer Research
    • 19 Aug 2020 Status changed from active, no longer recruiting to completed.
    • 24 Jun 2020 Results assessing phenotype and function of ICOS hi CD4 T cells from subset of evaluable patient from this study presented at the 111th Annual Meeting of the American Association for Cancer Research - II.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top